{"protocolSection":{"identificationModule":{"nctId":"NCT01994109","orgStudyIdInfo":{"id":"SN-SIAL-301"},"organization":{"fullName":"Supernus Pharmaceuticals, Inc.","class":"INDUSTRY"},"briefTitle":"Efficacy and Safety Study of MYOBLOC速 Followed by Open-Label Multiple-Treatment With MYOBLOC速 in the Treatment of Troublesome Sialorrhea in Adult Subjects","officialTitle":"A Phase 3, Multicenter, Double-Blind, Placebo-Controlled, Single-Treatment Efficacy and Safety Study of MYOBLOC速 (Part A) Followed by Open-Label, Multiple-Treatment With MYOBLOC速 (Part B) in the Treatment of Troublesome Sialorrhea in Adult Subjects","acronym":"MYSTICOL"},"statusModule":{"statusVerifiedDate":"2019-08","overallStatus":"COMPLETED","expandedAccessInfo":{"hasExpandedAccess":false},"startDateStruct":{"date":"2013-11"},"primaryCompletionDateStruct":{"date":"2016-01","type":"ACTUAL"},"completionDateStruct":{"date":"2017-01","type":"ACTUAL"},"studyFirstSubmitDate":"2013-11-14","studyFirstSubmitQcDate":"2013-11-20","studyFirstPostDateStruct":{"date":"2013-11-25","type":"ESTIMATED"},"resultsFirstSubmitDate":"2019-05-02","resultsFirstSubmitQcDate":"2019-08-14","resultsFirstPostDateStruct":{"date":"2019-08-15","type":"ACTUAL"},"dispFirstSubmitDate":"2017-02-09","dispFirstSubmitQcDate":"2017-02-09","dispFirstPostDateStruct":{"date":"2017-02-10","type":"ACTUAL"},"lastUpdateSubmitDate":"2021-07-09","lastUpdatePostDateStruct":{"date":"2021-07-13","type":"ACTUAL"}},"sponsorCollaboratorsModule":{"responsibleParty":{"type":"SPONSOR"},"leadSponsor":{"name":"Supernus Pharmaceuticals, Inc.","class":"INDUSTRY"}},"oversightModule":{"oversightHasDmc":false},"descriptionModule":{"briefSummary":"This study will evaluate the efficacy and safety of MYOBLOC in the treatment of Sialorrhea (drooling), which can be a symptom of many disease conditions. MYOBLOC will be injected directly into the salivary glands. MYOBLOC has been shown in previous trials to safely decrease saliva production, thereby demonstrating its potential as a safe and effective treatment for troublesome sialorrhea."},"conditionsModule":{"conditions":["Sialorrhea"],"keywords":["Sialorrhea","Parkinson's disease","Amyotrophic lateral sclerosis (ALS)","stroke","neuroleptics"]},"designModule":{"studyType":"INTERVENTIONAL","phases":["PHASE3"],"designInfo":{"allocation":"RANDOMIZED","interventionModel":"PARALLEL","primaryPurpose":"TREATMENT","maskingInfo":{"masking":"QUADRUPLE","whoMasked":["PARTICIPANT","CARE_PROVIDER","INVESTIGATOR","OUTCOMES_ASSESSOR"]}},"enrollmentInfo":{"count":187,"type":"ACTUAL"}},"armsInterventionsModule":{"armGroups":[{"label":"MYOBLOC 2500 U","type":"ACTIVE_COMPARATOR","description":"Subjects will receive specified dose of MYOBLOC","interventionNames":["Drug: MYOBLOC"]},{"label":"MYOBLOC 3500 U","type":"ACTIVE_COMPARATOR","description":"Subjects will receive specified dose of MYOBLOC","interventionNames":["Drug: MYOBLOC"]},{"label":"Placebo","type":"PLACEBO_COMPARATOR","description":"Subjects will receive volume matched Placebo","interventionNames":["Other: PLACEBO"]}],"interventions":[{"type":"DRUG","name":"MYOBLOC","description":"MYOBLOC (rimabotulinumtoxinB) Injection, or botulinum toxin type B, is the \"B\" serotype of botulinum toxin. It is the only commercially available \"B\" serotype, and also the only available botulinum toxin that does not require reconstitution for use.","armGroupLabels":["MYOBLOC 2500 U","MYOBLOC 3500 U"],"otherNames":["rimabotulinumtoxinB, botulinum toxin type B"]},{"type":"OTHER","name":"PLACEBO","armGroupLabels":["Placebo"],"otherNames":["volume-matched placebo"]}]},"outcomesModule":{"primaryOutcomes":[{"measure":"Unstimulated Salivary Flow Rate (USFR) at Week 4 Post-injection Visit (Part A)","description":"Change weight of expectorated saliva at a Week 4 post-injection visit.","timeFrame":"4 Weeks"},{"measure":"Clinical Global Impression Change (CGI-C) at Week 4 Post-injection (Part A)","description":"CGI-C was assessed on a 7-point scale ranging from \"very much improved\" to \"very much worse\" with 1 assigned to \"very much improved\" and 7 assigned to \"very much worse\"; ranging from a minimum score of 1 and a maximum score of 7.","timeFrame":"4 weeks"}]},"eligibilityModule":{"eligibilityCriteria":"Inclusion Criteria:\n\n* Seeking treatment for troublesome sialorrhea for at least 3 months that is occurring secondary to any disorder or related to any cause\n* Investigator sites will review entire list of inclusion criteria with potential subjects\n\nExclusion Criteria:\n\n* Any known prior exposure to botulinum toxin type B, or known adverse reaction or sensitivity to botulinum toxin type A, or known sensitivity to any of the MYOBLOC solution components.\n* Prior botulinum toxin treatment to the salivary glands at any time\n* Investigator sites will review entire list of exclusion criteria with potential subjects","healthyVolunteers":false,"sex":"ALL","minimumAge":"18 Years","maximumAge":"85 Years","stdAges":["ADULT","OLDER_ADULT"]},"contactsLocationsModule":{"overallOfficials":[{"name":"Najeebah Abdul-Musawir, MD,MBA","affiliation":"Supernus Pharmaceuticals, Inc.","role":"STUDY_DIRECTOR"}],"locations":[{"city":"Loma Linda","state":"California","zip":"92354","country":"United States","geoPoint":{"lat":34.04835,"lon":-117.26115}},{"city":"Los Angeles","state":"California","zip":"90033","country":"United States","geoPoint":{"lat":34.05223,"lon":-118.24368}},{"city":"National City","state":"California","zip":"91950","country":"United States","geoPoint":{"lat":32.67811,"lon":-117.0992}},{"city":"Aurora","state":"Colorado","zip":"80045","country":"United States","geoPoint":{"lat":39.72943,"lon":-104.83192}},{"city":"Washington","state":"District of Columbia","zip":"20007","country":"United States","geoPoint":{"lat":38.89511,"lon":-77.03637}},{"city":"Boca Raton","state":"Florida","zip":"33486","country":"United States","geoPoint":{"lat":26.3669,"lon":-80.13033}},{"city":"Port Charlotte","state":"Florida","zip":"33980","country":"United States","geoPoint":{"lat":26.97617,"lon":-82.09064}},{"city":"Carmel","state":"Indiana","zip":"46032","country":"United States","geoPoint":{"lat":39.97837,"lon":-86.11804}},{"city":"Baltimore","state":"Maryland","zip":"21287","country":"United States","geoPoint":{"lat":39.29038,"lon":-76.61219}},{"city":"Elkridge","state":"Maryland","zip":"21075","country":"United States","geoPoint":{"lat":39.21261,"lon":-76.71358}},{"city":"Detroit","state":"Michigan","zip":"48334","country":"United States","geoPoint":{"lat":42.33143,"lon":-83.04575}},{"city":"Saint Louis","state":"Missouri","zip":"63110","country":"United States","geoPoint":{"lat":38.62727,"lon":-90.19789}},{"city":"Edison","state":"New Jersey","zip":"08818","country":"United States","geoPoint":{"lat":40.51872,"lon":-74.4121}},{"city":"Albany","state":"New York","zip":"12208","country":"United States","geoPoint":{"lat":42.65258,"lon":-73.75623}},{"city":"New York","state":"New York","zip":"10003","country":"United States","geoPoint":{"lat":40.71427,"lon":-74.00597}},{"city":"Cincinnati","state":"Ohio","zip":"45219","country":"United States","geoPoint":{"lat":39.12713,"lon":-84.51435}},{"city":"Tulsa","state":"Oklahoma","zip":"74136","country":"United States","geoPoint":{"lat":36.15398,"lon":-95.99277}},{"city":"Port Royal","state":"South Carolina","zip":"29935","country":"United States","geoPoint":{"lat":32.37908,"lon":-80.69261}},{"city":"Cordova","state":"Tennessee","zip":"38018","country":"United States","geoPoint":{"lat":35.15565,"lon":-89.7762}},{"city":"Houston","state":"Texas","zip":"77030","country":"United States","geoPoint":{"lat":29.76328,"lon":-95.36327}},{"city":"San Antonio","state":"Texas","zip":"78229","country":"United States","geoPoint":{"lat":29.42412,"lon":-98.49363}},{"city":"Salt Lake City","state":"Utah","zip":"84132","country":"United States","geoPoint":{"lat":40.76078,"lon":-111.89105}},{"city":"Kirkland","state":"Washington","zip":"98034","country":"United States","geoPoint":{"lat":47.68149,"lon":-122.20874}},{"city":"Tacoma","state":"Washington","zip":"98409","country":"United States","geoPoint":{"lat":47.25288,"lon":-122.44429}},{"city":"Irkutsk","state":"Irkutsk Region","zip":"664079","country":"Russian Federation","geoPoint":{"lat":52.29778,"lon":104.29639}},{"city":"Vsevolozhsk","state":"Leningrad Region","zip":"188643","country":"Russian Federation","geoPoint":{"lat":60.01512,"lon":30.67314}},{"city":"St.Petersburg","state":"Petrodvorets","zip":"198510","country":"Russian Federation","geoPoint":{"lat":59.93863,"lon":30.31413}},{"city":"Krasnoyarsk","zip":"660037","country":"Russian Federation","geoPoint":{"lat":56.01839,"lon":92.86717}},{"city":"Dnipropetrovsk","zip":"49027","country":"Ukraine","geoPoint":{"lat":48.4593,"lon":35.03864}},{"city":"Ivano-Frankivsk","zip":"76008","country":"Ukraine","geoPoint":{"lat":48.9215,"lon":24.70972}},{"city":"Kharkiv","zip":"61068","country":"Ukraine","geoPoint":{"lat":49.98081,"lon":36.25272}},{"city":"Lviv","zip":"79010","country":"Ukraine","geoPoint":{"lat":49.83826,"lon":24.02324}},{"city":"Rivne","zip":"33010","country":"Ukraine","geoPoint":{"lat":50.62308,"lon":26.22743}},{"city":"Uzhgorod","zip":"88018","country":"Ukraine","geoPoint":{"lat":48.61667,"lon":22.3}}]},"referencesModule":{"references":[{"pmid":"21887710","type":"RESULT","citation":"Chinnapongse R, Gullo K, Nemeth P, Zhang Y, Griggs L. Safety and efficacy of botulinum toxin type B for treatment of sialorrhea in Parkinson's disease: a prospective double-blind trial. Mov Disord. 2012 Feb;27(2):219-26. doi: 10.1002/mds.23929. Epub 2011 Sep 1."},{"pmid":"14718694","type":"RESULT","citation":"Ondo WG, Hunter C, Moore W. A double-blind placebo-controlled trial of botulinum toxin B for sialorrhea in Parkinson's disease. Neurology. 2004 Jan 13;62(1):37-40. doi: 10.1212/01.wnl.0000101713.81253.4c."},{"pmid":"31930364","type":"DERIVED","citation":"Isaacson SH, Ondo W, Jackson CE, Trosch RM, Molho E, Pagan F, Lew M, Dashtipour K, Clinch T, Espay AJ; MYSTICOL Study Group. Safety and Efficacy of RimabotulinumtoxinB for Treatment of Sialorrhea in Adults: A Randomized Clinical Trial. JAMA Neurol. 2020 Apr 1;77(4):461-469. doi: 10.1001/jamaneurol.2019.4565."}]}},"resultsSection":{"participantFlowModule":{"preAssignmentDetails":"DB: Double Blind (Part A) OL: Open Label (Part B)","recruitmentDetails":"The study was conducted at 33 sites including United States, Russia and Ukraine.","groups":[{"id":"FG000","title":"DB: MYOBLOC 2500 U","description":"Participants will receive specified dose of MYOBLOC"},{"id":"FG001","title":"DB: MYOBLOC 3500 U","description":"Participants will receive specified dose of MYOBLOC"},{"id":"FG002","title":"DB: Placebo","description":"Participants will receive volume matched Placebo"},{"id":"FG003","title":"OL: ALL MYOBLOC","description":"All Participants were to receive 3500 U MYOBLOC but could receive lower doses at investigator discretion."}],"periods":[{"title":"Double-blind Phase (Part A)","milestones":[{"type":"STARTED","achievements":[{"groupId":"FG000","numSubjects":"63"},{"groupId":"FG001","numSubjects":"64"},{"groupId":"FG002","numSubjects":"60"},{"groupId":"FG003","numSubjects":"0"}]},{"type":"COMPLETED","achievements":[{"groupId":"FG000","numSubjects":"62"},{"groupId":"FG001","numSubjects":"61"},{"groupId":"FG002","numSubjects":"53"},{"groupId":"FG003","numSubjects":"0"}]},{"type":"NOT COMPLETED","achievements":[{"groupId":"FG000","numSubjects":"1"},{"groupId":"FG001","numSubjects":"3"},{"groupId":"FG002","numSubjects":"7"},{"groupId":"FG003","numSubjects":"0"}]}]},{"title":"Open-label Phase (Part B)","milestones":[{"type":"STARTED","achievements":[{"groupId":"FG000","numSubjects":"0"},{"groupId":"FG001","numSubjects":"0"},{"groupId":"FG002","comment":"No placebo group in Part B.","numSubjects":"0"},{"groupId":"FG003","comment":"61 from 2500 U group, 57 from 3500 U group, 52 from Placebo group continued to Part B","numSubjects":"170"}]},{"type":"COMPLETED","achievements":[{"groupId":"FG000","numSubjects":"0"},{"groupId":"FG001","numSubjects":"0"},{"groupId":"FG002","comment":"No placebo group in Part B.","numSubjects":"0"},{"groupId":"FG003","numSubjects":"128"}]},{"type":"NOT COMPLETED","achievements":[{"groupId":"FG000","numSubjects":"0"},{"groupId":"FG001","numSubjects":"0"},{"groupId":"FG002","numSubjects":"0"},{"groupId":"FG003","numSubjects":"42"}]}]}]},"baselineCharacteristicsModule":{"populationDescription":"Demographic Characteristics of intent-to-treat (ITT) Population.","groups":[{"id":"BG000","title":"MYOBLOC 2500 U","description":"Subjects were dosed per treatment assignment of 2500 U MYOBLOC."},{"id":"BG001","title":"MYOBLOC 3500 U","description":"Subjects were dosed per treatment assignment of 3500 U MYOBLOC."},{"id":"BG002","title":"PLACEBO","description":"Placebo was dosed as an exact match of MYOBLOC."},{"id":"BG003","title":"Total","description":"Total of all reporting groups"}],"denoms":[{"units":"Participants","counts":[{"groupId":"BG000","value":"63"},{"groupId":"BG001","value":"64"},{"groupId":"BG002","value":"57"},{"groupId":"BG003","value":"184"}]}],"measures":[{"title":"Age, Categorical","paramType":"COUNT_OF_PARTICIPANTS","unitOfMeasure":"Participants","classes":[{"categories":[{"title":"<=18 years","measurements":[{"groupId":"BG000","value":"0"},{"groupId":"BG001","value":"0"},{"groupId":"BG002","value":"0"},{"groupId":"BG003","value":"0"}]},{"title":"Between 18 and 65 years","measurements":[{"groupId":"BG000","value":"29"},{"groupId":"BG001","value":"25"},{"groupId":"BG002","value":"24"},{"groupId":"BG003","value":"78"}]},{"title":">=65 years","measurements":[{"groupId":"BG000","value":"34"},{"groupId":"BG001","value":"39"},{"groupId":"BG002","value":"33"},{"groupId":"BG003","value":"106"}]}]}]},{"title":"Age, Continuous","paramType":"MEAN","dispersionType":"STANDARD_DEVIATION","unitOfMeasure":"years","classes":[{"categories":[{"measurements":[{"groupId":"BG000","value":"62.6","spread":"13.0"},{"groupId":"BG001","value":"64.6","spread":"14.0"},{"groupId":"BG002","value":"64.1","spread":"13.1"},{"groupId":"BG003","value":"63.8","spread":"13.4"}]}]}]},{"title":"Sex: Female, Male","paramType":"COUNT_OF_PARTICIPANTS","unitOfMeasure":"Participants","classes":[{"categories":[{"title":"Female","measurements":[{"groupId":"BG000","value":"15"},{"groupId":"BG001","value":"9"},{"groupId":"BG002","value":"16"},{"groupId":"BG003","value":"40"}]},{"title":"Male","measurements":[{"groupId":"BG000","value":"48"},{"groupId":"BG001","value":"55"},{"groupId":"BG002","value":"41"},{"groupId":"BG003","value":"144"}]}]}]},{"title":"Ethnicity (NIH/OMB)","paramType":"COUNT_OF_PARTICIPANTS","unitOfMeasure":"Participants","classes":[{"categories":[{"title":"Hispanic or Latino","measurements":[{"groupId":"BG000","value":"5"},{"groupId":"BG001","value":"2"},{"groupId":"BG002","value":"1"},{"groupId":"BG003","value":"8"}]},{"title":"Not Hispanic or Latino","measurements":[{"groupId":"BG000","value":"58"},{"groupId":"BG001","value":"62"},{"groupId":"BG002","value":"56"},{"groupId":"BG003","value":"176"}]},{"title":"Unknown or Not Reported","measurements":[{"groupId":"BG000","value":"0"},{"groupId":"BG001","value":"0"},{"groupId":"BG002","value":"0"},{"groupId":"BG003","value":"0"}]}]}]},{"title":"Race (NIH/OMB)","paramType":"COUNT_OF_PARTICIPANTS","unitOfMeasure":"Participants","classes":[{"categories":[{"title":"American Indian or Alaska Native","measurements":[{"groupId":"BG000","value":"0"},{"groupId":"BG001","value":"1"},{"groupId":"BG002","value":"0"},{"groupId":"BG003","value":"1"}]},{"title":"Asian","measurements":[{"groupId":"BG000","value":"1"},{"groupId":"BG001","value":"0"},{"groupId":"BG002","value":"1"},{"groupId":"BG003","value":"2"}]},{"title":"Native Hawaiian or Other Pacific Islander","measurements":[{"groupId":"BG000","value":"0"},{"groupId":"BG001","value":"0"},{"groupId":"BG002","value":"0"},{"groupId":"BG003","value":"0"}]},{"title":"Black or African American","measurements":[{"groupId":"BG000","value":"2"},{"groupId":"BG001","value":"1"},{"groupId":"BG002","value":"1"},{"groupId":"BG003","value":"4"}]},{"title":"White","measurements":[{"groupId":"BG000","value":"60"},{"groupId":"BG001","value":"60"},{"groupId":"BG002","value":"55"},{"groupId":"BG003","value":"175"}]},{"title":"More than one race","measurements":[{"groupId":"BG000","value":"0"},{"groupId":"BG001","value":"0"},{"groupId":"BG002","value":"0"},{"groupId":"BG003","value":"0"}]},{"title":"Unknown or Not Reported","measurements":[{"groupId":"BG000","value":"0"},{"groupId":"BG001","value":"2"},{"groupId":"BG002","value":"0"},{"groupId":"BG003","value":"2"}]}]}]}]},"outcomeMeasuresModule":{"outcomeMeasures":[{"type":"PRIMARY","title":"Unstimulated Salivary Flow Rate (USFR) at Week 4 Post-injection Visit (Part A)","description":"Change weight of expectorated saliva at a Week 4 post-injection visit.","populationDescription":"The per protocol included subjects with a minimum USFR of 0.2 g/min.","reportingStatus":"POSTED","paramType":"LEAST_SQUARES_MEAN","dispersionType":"Standard Error","unitOfMeasure":"g/minute","timeFrame":"4 Weeks","groups":[{"id":"OG000","title":"MYOBLOC 2500 U","description":"Subjects were dosed per treatment assignment of 2500 U MYOBLOC."},{"id":"OG001","title":"MYOBLOC 3500 U","description":"Subjects were dosed per treatment assignment of 3500 U MYOBLOC"},{"id":"OG002","title":"Placebo","description":"Placebo was dosed as an exact match of MYOBLOC."}],"denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"63"},{"groupId":"OG001","value":"64"},{"groupId":"OG002","value":"57"}]}],"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"-0.37","spread":"0.03"},{"groupId":"OG001","value":"-0.36","spread":"0.03"},{"groupId":"OG002","value":"-0.07","spread":"0.03"}]}]}],"analyses":[{"groupIds":["OG001","OG002"],"nonInferiorityType":"SUPERIORITY","pValue":"<0.0001","statisticalMethod":"ANCOVA"},{"groupIds":["OG000","OG002"],"nonInferiorityType":"SUPERIORITY","pValue":"<0.0001","statisticalMethod":"ANCOVA"}]},{"type":"PRIMARY","title":"Clinical Global Impression Change (CGI-C) at Week 4 Post-injection (Part A)","description":"CGI-C was assessed on a 7-point scale ranging from \"very much improved\" to \"very much worse\" with 1 assigned to \"very much improved\" and 7 assigned to \"very much worse\"; ranging from a minimum score of 1 and a maximum score of 7.","populationDescription":"Per protocol the intent-to-treat population who were injected with study medication and had at least 1 post injection CGI-C measurement up to week 4 (inclusive).","reportingStatus":"POSTED","paramType":"LEAST_SQUARES_MEAN","dispersionType":"Standard Error","unitOfMeasure":"score on a scale","timeFrame":"4 weeks","groups":[{"id":"OG000","title":"MYOBLOC 2500 U","description":"Subjects were dosed per treatment assignment of 2500 U MYOBLOC."},{"id":"OG001","title":"MYOBLOC 3500 U","description":"Subjects were dosed per treatment assignment of 3500 U MYOBLOC."},{"id":"OG002","title":"Placebo","description":"Placebo was dosed as an exact match of MYOBLOC."}],"denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"63"},{"groupId":"OG001","value":"64"},{"groupId":"OG002","value":"60"}]}],"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"2.38","spread":"0.12"},{"groupId":"OG001","value":"2.45","spread":"0.12"},{"groupId":"OG002","value":"3.59","spread":"0.13"}]}]}],"analyses":[{"groupIds":["OG001","OG002"],"nonInferiorityType":"SUPERIORITY","pValue":"<0.0001","statisticalMethod":"ANCOVA"},{"groupIds":["OG000","OG002"],"nonInferiorityType":"SUPERIORITY","pValue":"<0.0001","statisticalMethod":"ANCOVA"}]}]},"adverseEventsModule":{"frequencyThreshold":"5","timeFrame":"Part A: 13-Week Post-Injection Period; Part B: 4 Sessions of 13-Week (+/- 2 Weeks) Post-Injection Periods","description":"Part A (Session 1): Serious TEAEs Reported During Double-Blind Phase (Safety Population) Part B (Sessions 2-5): Serious TEAEs Reported During Open-Label Phase (OL Population)","eventGroups":[{"id":"EG000","title":"MYOBLOC 2500 U (Part A)","description":"Participants received specified dose of MYOBLOC. Participants were evaluated for 13 weeks following the injection.","deathsNumAffected":0,"deathsNumAtRisk":63,"seriousNumAffected":1,"seriousNumAtRisk":63,"otherNumAffected":44,"otherNumAtRisk":63},{"id":"EG001","title":"MYOBLOC 3500 U (Part A)","description":"Participants received specified dose of MYOBLOC. Participants were evaluated for 13 weeks following the injection.","deathsNumAffected":2,"deathsNumAtRisk":64,"seriousNumAffected":4,"seriousNumAtRisk":64,"otherNumAffected":38,"otherNumAtRisk":64},{"id":"EG002","title":"Placebo (Part A)","description":"Participants received volume matched Placebo. Participants were evaluated for 13 weeks following the injection.","deathsNumAffected":1,"deathsNumAtRisk":60,"seriousNumAffected":4,"seriousNumAtRisk":60,"otherNumAffected":16,"otherNumAtRisk":60},{"id":"EG003","title":"OL: ALL MYOBLOC (Part B)","description":"Participants received Open Label treatment with 3500 U (decreased dose at investigator discretion) every 13 weeks for a maximum of 4 treatment sessions.","deathsNumAffected":9,"deathsNumAtRisk":170,"seriousNumAffected":32,"seriousNumAtRisk":170,"otherNumAffected":143,"otherNumAtRisk":170}],"seriousEvents":[{"term":"Cardio-respiratory arrest","organSystem":"Cardiac disorders","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":63},{"groupId":"EG001","numAffected":1,"numAtRisk":64},{"groupId":"EG002","numAffected":0,"numAtRisk":60},{"groupId":"EG003","numAffected":2,"numAtRisk":170}]},{"term":"Small intestinal obstruction","organSystem":"Gastrointestinal disorders","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":63},{"groupId":"EG001","numAffected":0,"numAtRisk":64},{"groupId":"EG002","numAffected":1,"numAtRisk":60},{"groupId":"EG003","numAffected":0,"numAtRisk":170}]},{"term":"Malaise","organSystem":"General disorders","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":63},{"groupId":"EG001","numAffected":1,"numAtRisk":64},{"groupId":"EG002","numAffected":0,"numAtRisk":60},{"groupId":"EG003","numAffected":1,"numAtRisk":170}]},{"term":"Pneumonia","organSystem":"Infections and infestations","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":63},{"groupId":"EG001","numAffected":1,"numAtRisk":64},{"groupId":"EG002","numAffected":0,"numAtRisk":60},{"groupId":"EG003","numAffected":5,"numAtRisk":170}]},{"term":"Urinary tract infection","organSystem":"Infections and infestations","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":1,"numAtRisk":63},{"groupId":"EG001","numAffected":0,"numAtRisk":64},{"groupId":"EG002","numAffected":0,"numAtRisk":60},{"groupId":"EG003","numAffected":3,"numAtRisk":170}]},{"term":"Urosepsis","organSystem":"Infections and infestations","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":63},{"groupId":"EG001","numAffected":0,"numAtRisk":64},{"groupId":"EG002","numAffected":1,"numAtRisk":60},{"groupId":"EG003","numAffected":0,"numAtRisk":170}]},{"term":"Brain cancer metastatic","organSystem":"Neoplasms benign, malignant and unspecified (incl cysts and polyps)","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":63},{"groupId":"EG001","numAffected":1,"numAtRisk":64},{"groupId":"EG002","numAffected":0,"numAtRisk":60},{"groupId":"EG003","numAffected":0,"numAtRisk":170}]},{"term":"Nodular melanoma","organSystem":"Neoplasms benign, malignant and unspecified (incl cysts and polyps)","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":63},{"groupId":"EG001","numAffected":0,"numAtRisk":64},{"groupId":"EG002","numAffected":1,"numAtRisk":60},{"groupId":"EG003","numAffected":0,"numAtRisk":170}]},{"term":"Syncope","organSystem":"Nervous system disorders","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":63},{"groupId":"EG001","numAffected":1,"numAtRisk":64},{"groupId":"EG002","numAffected":0,"numAtRisk":60},{"groupId":"EG003","numAffected":2,"numAtRisk":170}]},{"term":"Pneumonia aspiration","organSystem":"Respiratory, thoracic and mediastinal disorders","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":63},{"groupId":"EG001","numAffected":1,"numAtRisk":64},{"groupId":"EG002","numAffected":0,"numAtRisk":60},{"groupId":"EG003","numAffected":1,"numAtRisk":170}]},{"term":"Circulatory collapse","organSystem":"Vascular disorders","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":63},{"groupId":"EG001","numAffected":0,"numAtRisk":64},{"groupId":"EG002","numAffected":1,"numAtRisk":60},{"groupId":"EG003","numAffected":0,"numAtRisk":170}]},{"term":"Atrial fibrillaiton","organSystem":"Cardiac disorders","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":63},{"groupId":"EG001","numAffected":0,"numAtRisk":64},{"groupId":"EG002","numAffected":0,"numAtRisk":60},{"groupId":"EG003","numAffected":1,"numAtRisk":170}]},{"term":"Cardiac arrest","organSystem":"Cardiac disorders","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":63},{"groupId":"EG001","numAffected":0,"numAtRisk":64},{"groupId":"EG002","numAffected":0,"numAtRisk":60},{"groupId":"EG003","numAffected":1,"numAtRisk":170}]},{"term":"Visual acuity reduced","organSystem":"Eye disorders","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":63},{"groupId":"EG001","numAffected":0,"numAtRisk":64},{"groupId":"EG002","numAffected":0,"numAtRisk":60},{"groupId":"EG003","numAffected":1,"numAtRisk":170}]},{"term":"Dysphagia","organSystem":"Gastrointestinal disorders","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":63},{"groupId":"EG001","numAffected":0,"numAtRisk":64},{"groupId":"EG002","numAffected":0,"numAtRisk":60},{"groupId":"EG003","numAffected":1,"numAtRisk":170}]},{"term":"Asthenia","organSystem":"General disorders","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":63},{"groupId":"EG001","numAffected":0,"numAtRisk":64},{"groupId":"EG002","numAffected":0,"numAtRisk":60},{"groupId":"EG003","numAffected":1,"numAtRisk":170}]},{"term":"Fatigue","organSystem":"General disorders","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":63},{"groupId":"EG001","numAffected":0,"numAtRisk":64},{"groupId":"EG002","numAffected":0,"numAtRisk":60},{"groupId":"EG003","numAffected":1,"numAtRisk":170}]},{"term":"Hypothermia","organSystem":"General disorders","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":63},{"groupId":"EG001","numAffected":0,"numAtRisk":64},{"groupId":"EG002","numAffected":0,"numAtRisk":60},{"groupId":"EG003","numAffected":1,"numAtRisk":170}]},{"term":"Cellulitis","organSystem":"Infections and infestations","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":63},{"groupId":"EG001","numAffected":0,"numAtRisk":64},{"groupId":"EG002","numAffected":0,"numAtRisk":60},{"groupId":"EG003","numAffected":1,"numAtRisk":170}]},{"term":"Fungal skin infection","organSystem":"Infections and infestations","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":63},{"groupId":"EG001","numAffected":0,"numAtRisk":64},{"groupId":"EG002","numAffected":0,"numAtRisk":60},{"groupId":"EG003","numAffected":1,"numAtRisk":170}]},{"term":"Herpes zoster","organSystem":"Infections and infestations","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":63},{"groupId":"EG001","numAffected":0,"numAtRisk":64},{"groupId":"EG002","numAffected":0,"numAtRisk":60},{"groupId":"EG003","numAffected":1,"numAtRisk":170}]},{"term":"Sepsis","organSystem":"Infections and infestations","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":63},{"groupId":"EG001","numAffected":0,"numAtRisk":64},{"groupId":"EG002","numAffected":0,"numAtRisk":60},{"groupId":"EG003","numAffected":1,"numAtRisk":170}]},{"term":"Staphylococcal infection","organSystem":"Infections and infestations","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":63},{"groupId":"EG001","numAffected":0,"numAtRisk":64},{"groupId":"EG002","numAffected":0,"numAtRisk":60},{"groupId":"EG003","numAffected":1,"numAtRisk":170}]},{"term":"Burns first degree","organSystem":"Injury, poisoning and procedural complications","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":63},{"groupId":"EG001","numAffected":0,"numAtRisk":64},{"groupId":"EG002","numAffected":0,"numAtRisk":60},{"groupId":"EG003","numAffected":1,"numAtRisk":170}]},{"term":"Burns second degree","organSystem":"Injury, poisoning and procedural complications","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":63},{"groupId":"EG001","numAffected":0,"numAtRisk":64},{"groupId":"EG002","numAffected":0,"numAtRisk":60},{"groupId":"EG003","numAffected":1,"numAtRisk":170}]},{"term":"Cervical vertebral fracture","organSystem":"Injury, poisoning and procedural complications","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":63},{"groupId":"EG001","numAffected":0,"numAtRisk":64},{"groupId":"EG002","numAffected":0,"numAtRisk":60},{"groupId":"EG003","numAffected":1,"numAtRisk":170}]},{"term":"Facial bones fracture","organSystem":"Injury, poisoning and procedural complications","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":63},{"groupId":"EG001","numAffected":0,"numAtRisk":64},{"groupId":"EG002","numAffected":0,"numAtRisk":60},{"groupId":"EG003","numAffected":1,"numAtRisk":170}]},{"term":"Fall","organSystem":"Injury, poisoning and procedural complications","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":63},{"groupId":"EG001","numAffected":0,"numAtRisk":64},{"groupId":"EG002","numAffected":0,"numAtRisk":60},{"groupId":"EG003","numAffected":1,"numAtRisk":170}]},{"term":"Hip fracture","organSystem":"Injury, poisoning and procedural complications","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":63},{"groupId":"EG001","numAffected":0,"numAtRisk":64},{"groupId":"EG002","numAffected":0,"numAtRisk":60},{"groupId":"EG003","numAffected":1,"numAtRisk":170}]},{"term":"Lumbar vertebral fracture","organSystem":"Injury, poisoning and procedural complications","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":63},{"groupId":"EG001","numAffected":0,"numAtRisk":64},{"groupId":"EG002","numAffected":0,"numAtRisk":60},{"groupId":"EG003","numAffected":1,"numAtRisk":170}]},{"term":"Subdural haematoma","organSystem":"Injury, poisoning and procedural complications","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":63},{"groupId":"EG001","numAffected":0,"numAtRisk":64},{"groupId":"EG002","numAffected":0,"numAtRisk":60},{"groupId":"EG003","numAffected":1,"numAtRisk":170}]},{"term":"Malnutrition","organSystem":"Metabolism and nutrition disorders","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":63},{"groupId":"EG001","numAffected":0,"numAtRisk":64},{"groupId":"EG002","numAffected":0,"numAtRisk":60},{"groupId":"EG003","numAffected":1,"numAtRisk":170}]},{"term":"Arthralgia","organSystem":"Musculoskeletal and connective tissue disorders","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":63},{"groupId":"EG001","numAffected":0,"numAtRisk":64},{"groupId":"EG002","numAffected":0,"numAtRisk":60},{"groupId":"EG003","numAffected":1,"numAtRisk":170}]},{"term":"Lung neoplasm","organSystem":"Neoplasms benign, malignant and unspecified (incl cysts and polyps)","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":63},{"groupId":"EG001","numAffected":0,"numAtRisk":64},{"groupId":"EG002","numAffected":0,"numAtRisk":60},{"groupId":"EG003","numAffected":1,"numAtRisk":170}]},{"term":"Pharyngeal cancer","organSystem":"Neoplasms benign, malignant and unspecified (incl cysts and polyps)","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":63},{"groupId":"EG001","numAffected":0,"numAtRisk":64},{"groupId":"EG002","numAffected":0,"numAtRisk":60},{"groupId":"EG003","numAffected":1,"numAtRisk":170}]},{"term":"Amyotrophic lateral sclerosis","organSystem":"Nervous system disorders","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":63},{"groupId":"EG001","numAffected":0,"numAtRisk":64},{"groupId":"EG002","numAffected":0,"numAtRisk":60},{"groupId":"EG003","numAffected":1,"numAtRisk":170}]},{"term":"Dementia with Lewy bodies","organSystem":"Nervous system disorders","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":63},{"groupId":"EG001","numAffected":0,"numAtRisk":64},{"groupId":"EG002","numAffected":0,"numAtRisk":60},{"groupId":"EG003","numAffected":1,"numAtRisk":170}]},{"term":"Encephalopathy","organSystem":"Nervous system disorders","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":63},{"groupId":"EG001","numAffected":0,"numAtRisk":64},{"groupId":"EG002","numAffected":0,"numAtRisk":60},{"groupId":"EG003","numAffected":2,"numAtRisk":170}]},{"term":"Ischaemic stroke","organSystem":"Nervous system disorders","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":63},{"groupId":"EG001","numAffected":0,"numAtRisk":64},{"groupId":"EG002","numAffected":0,"numAtRisk":60},{"groupId":"EG003","numAffected":1,"numAtRisk":170}]},{"term":"Parkinson's disease","organSystem":"Nervous system disorders","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":63},{"groupId":"EG001","numAffected":0,"numAtRisk":64},{"groupId":"EG002","numAffected":0,"numAtRisk":60},{"groupId":"EG003","numAffected":1,"numAtRisk":170}]},{"term":"Parkinsonism","organSystem":"Nervous system disorders","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":63},{"groupId":"EG001","numAffected":0,"numAtRisk":64},{"groupId":"EG002","numAffected":0,"numAtRisk":60},{"groupId":"EG003","numAffected":1,"numAtRisk":170}]},{"term":"Radiculopathy","organSystem":"Nervous system disorders","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":63},{"groupId":"EG001","numAffected":0,"numAtRisk":64},{"groupId":"EG002","numAffected":0,"numAtRisk":60},{"groupId":"EG003","numAffected":1,"numAtRisk":170}]},{"term":"Transient ischaemic attack","organSystem":"Nervous system disorders","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":63},{"groupId":"EG001","numAffected":0,"numAtRisk":64},{"groupId":"EG002","numAffected":0,"numAtRisk":60},{"groupId":"EG003","numAffected":1,"numAtRisk":170}]},{"term":"Vocal cord paralysis","organSystem":"Nervous system disorders","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":63},{"groupId":"EG001","numAffected":0,"numAtRisk":64},{"groupId":"EG002","numAffected":0,"numAtRisk":60},{"groupId":"EG003","numAffected":1,"numAtRisk":170}]},{"term":"Aggression","organSystem":"Psychiatric disorders","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":63},{"groupId":"EG001","numAffected":0,"numAtRisk":64},{"groupId":"EG002","numAffected":0,"numAtRisk":60},{"groupId":"EG003","numAffected":1,"numAtRisk":170}]},{"term":"Aspiration","organSystem":"Respiratory, thoracic and mediastinal disorders","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":63},{"groupId":"EG001","numAffected":0,"numAtRisk":64},{"groupId":"EG002","numAffected":0,"numAtRisk":60},{"groupId":"EG003","numAffected":1,"numAtRisk":170}]},{"term":"Pulmonary embolism","organSystem":"Respiratory, thoracic and mediastinal disorders","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":63},{"groupId":"EG001","numAffected":0,"numAtRisk":64},{"groupId":"EG002","numAffected":0,"numAtRisk":60},{"groupId":"EG003","numAffected":0,"numAtRisk":170}]},{"term":"Respiratory failure","organSystem":"Respiratory, thoracic and mediastinal disorders","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":63},{"groupId":"EG001","numAffected":0,"numAtRisk":64},{"groupId":"EG002","numAffected":0,"numAtRisk":60},{"groupId":"EG003","numAffected":3,"numAtRisk":170}]},{"term":"Arteriosclerosis","organSystem":"Vascular disorders","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":63},{"groupId":"EG001","numAffected":0,"numAtRisk":64},{"groupId":"EG002","numAffected":0,"numAtRisk":60},{"groupId":"EG003","numAffected":1,"numAtRisk":170}]},{"term":"Deep vein thrombosis","organSystem":"Vascular disorders","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":63},{"groupId":"EG001","numAffected":0,"numAtRisk":64},{"groupId":"EG002","numAffected":0,"numAtRisk":60},{"groupId":"EG003","numAffected":1,"numAtRisk":170}]}],"otherEvents":[{"term":"Dental caries","organSystem":"Gastrointestinal disorders","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":5,"numAtRisk":63},{"groupId":"EG001","numAffected":3,"numAtRisk":64},{"groupId":"EG002","numAffected":2,"numAtRisk":60},{"groupId":"EG003","numAffected":50,"numAtRisk":170}]},{"term":"Dry mouth","organSystem":"Gastrointestinal disorders","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":24,"numAtRisk":63},{"groupId":"EG001","numAffected":29,"numAtRisk":64},{"groupId":"EG002","numAffected":5,"numAtRisk":60},{"groupId":"EG003","numAffected":73,"numAtRisk":170}]},{"term":"Dysphagia","organSystem":"Gastrointestinal disorders","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":7,"numAtRisk":63},{"groupId":"EG001","numAffected":3,"numAtRisk":64},{"groupId":"EG002","numAffected":1,"numAtRisk":60},{"groupId":"EG003","numAffected":21,"numAtRisk":170}]},{"term":"Fall","organSystem":"Injury, poisoning and procedural complications","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":4,"numAtRisk":63},{"groupId":"EG001","numAffected":3,"numAtRisk":64},{"groupId":"EG002","numAffected":4,"numAtRisk":60},{"groupId":"EG003","numAffected":28,"numAtRisk":170}]},{"term":"Dizziness","organSystem":"Nervous system disorders","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":4,"numAtRisk":63},{"groupId":"EG001","numAffected":0,"numAtRisk":64},{"groupId":"EG002","numAffected":0,"numAtRisk":60},{"groupId":"EG003","numAffected":10,"numAtRisk":170}]},{"term":"Cough","organSystem":"Respiratory, thoracic and mediastinal disorders","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":63},{"groupId":"EG001","numAffected":0,"numAtRisk":64},{"groupId":"EG002","numAffected":4,"numAtRisk":60},{"groupId":"EG003","numAffected":8,"numAtRisk":170}]},{"term":"Urinary tract infection","organSystem":"Infections and infestations","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":63},{"groupId":"EG001","numAffected":0,"numAtRisk":64},{"groupId":"EG002","numAffected":0,"numAtRisk":60},{"groupId":"EG003","numAffected":12,"numAtRisk":170}]},{"term":"Contusion","organSystem":"Injury, poisoning and procedural complications","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":63},{"groupId":"EG001","numAffected":0,"numAtRisk":64},{"groupId":"EG002","numAffected":0,"numAtRisk":60},{"groupId":"EG003","numAffected":11,"numAtRisk":170}]},{"term":"Weight decreased","organSystem":"Investigations","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":63},{"groupId":"EG001","numAffected":0,"numAtRisk":64},{"groupId":"EG002","numAffected":0,"numAtRisk":60},{"groupId":"EG003","numAffected":10,"numAtRisk":170}]}]},"moreInfoModule":{"certainAgreement":{"piSponsorEmployee":false,"restrictionType":"OTHER","restrictiveAgreement":true,"otherDetails":"Sponsor has the first right, within 9 months following the later to occur 1) close out meeting or 2) Sponsor possessing all data, to publish the lead paper. Following the foregoing, Institution has the right to publish the results provided the Institution provides a Publications Committee, which includes the Sponsor, with a draft at least 30 days before submission. At Sponsor's request, Institution shall withhold publication for 45 days to allow filing of a patent application."},"pointOfContact":{"title":"Regulatory Affairs Associate","organization":"Solstice Neurosciences","email":"regulatoryaffairs@usworldmeds.com"}}},"derivedSection":{"miscInfoModule":{"versionHolder":"2024-02-14"},"conditionBrowseModule":{"meshes":[{"id":"D000012798","term":"Sialorrhea"}],"ancestors":[{"id":"D000012466","term":"Salivary Gland Diseases"},{"id":"D000009059","term":"Mouth Diseases"},{"id":"D000009057","term":"Stomatognathic Diseases"}],"browseLeaves":[{"id":"M21996","name":"Stroke","relevance":"LOW"},{"id":"M12903","name":"Parkinson Disease","relevance":"LOW"},{"id":"M15105","name":"Sclerosis","relevance":"LOW"},{"id":"M18569","name":"Motor Neuron Disease","relevance":"LOW"},{"id":"M3714","name":"Amyotrophic Lateral Sclerosis","relevance":"LOW"},{"id":"M15294","name":"Sialorrhea","asFound":"Sialorrhea","relevance":"HIGH"},{"id":"M14975","name":"Salivary Gland Diseases","relevance":"LOW"},{"id":"M11709","name":"Mouth Diseases","relevance":"LOW"},{"id":"M11707","name":"Stomatognathic Diseases","relevance":"LOW"},{"id":"T349","name":"Amyotrophic Lateral Sclerosis","relevance":"LOW"},{"id":"T4699","name":"Primary Lateral Sclerosis","relevance":"LOW"}],"browseBranches":[{"abbrev":"BC10","name":"Nervous System Diseases"},{"abbrev":"BC14","name":"Heart and Blood Diseases"},{"abbrev":"All","name":"All Conditions"},{"abbrev":"BC23","name":"Symptoms and General Pathology"},{"abbrev":"BC18","name":"Nutritional and Metabolic Diseases"},{"abbrev":"BC07","name":"Mouth and Tooth Diseases"},{"abbrev":"Rare","name":"Rare Diseases"}]},"interventionBrowseModule":{"meshes":[{"id":"C000096323","term":"rimabotulinumtoxinB"},{"id":"D000001905","term":"Botulinum Toxins"}],"ancestors":[{"id":"D000065087","term":"Acetylcholine Release Inhibitors"},{"id":"D000049990","term":"Membrane Transport Modulators"},{"id":"D000045504","term":"Molecular Mechanisms of Pharmacological Action"},{"id":"D000018678","term":"Cholinergic Agents"},{"id":"D000018377","term":"Neurotransmitter Agents"},{"id":"D000045505","term":"Physiological Effects of Drugs"},{"id":"D000018726","term":"Anti-Dyskinesia Agents"}],"browseLeaves":[{"id":"M4873","name":"Botulinum Toxins","asFound":"250","relevance":"HIGH"},{"id":"M250157","name":"abobotulinumtoxinA","relevance":"LOW"},{"id":"M20947","name":"Botulinum Toxins, Type A","relevance":"LOW"},{"id":"M16594","name":"Antipsychotic Agents","relevance":"LOW"},{"id":"M254652","name":"rimabotulinumtoxinB","asFound":"Gemcabene","relevance":"HIGH"},{"id":"M3163","name":"Acetylcholine","relevance":"LOW"},{"id":"M20448","name":"Cholinergic Agents","relevance":"LOW"},{"id":"M20194","name":"Neurotransmitter Agents","relevance":"LOW"}],"browseBranches":[{"abbrev":"All","name":"All Drugs and Chemicals"},{"abbrev":"CNSDep","name":"Central Nervous System Depressants"},{"abbrev":"PsychDr","name":"Psychotropic Drugs"},{"abbrev":"AnDyAg","name":"Anti-Dyskinesia Agents"},{"abbrev":"VaDiAg","name":"Vasodilator Agents"}]}},"hasResults":true}